Neuroprotective Peptides for Retinal Degeneration
Retinal Neuroprotection
75% photoreceptor preservation
PEDF-derived H105A peptide eye drops preserved up to 75% of photoreceptors after one week of treatment in a mouse model of retinitis pigmentosa.
Bernardo-Colon et al., Communications Medicine, 2025
Bernardo-Colon et al., Communications Medicine, 2025
View as imageThe retina is neural tissue. Its photoreceptors, ganglion cells, and retinal pigment epithelium are neurons and support cells that degenerate in diseases ranging from retinitis pigmentosa (RP) to age-related macular degeneration (AMD) to glaucoma. Because the retina is part of the central nervous system, neuroprotective peptides that work in the brain can also protect retinal neurons. PACAP, PEDF-derived fragments, GLP-1 receptor agonists, CNTF, and GHRH analogs have all demonstrated retinal protection in preclinical models. Some have reached clinical testing. None has yet become a standard treatment for retinal degeneration, but the pipeline is deeper than at any point in the field's history. The convergence of peptide biology, topical delivery technology, and a better understanding of photoreceptor death pathways is creating opportunities that did not exist a decade ago.
Key Takeaways
- PEDF-derived H105A peptide eye drops preserved up to 75% of photoreceptors after one week in RP mice, with 10% of applied peptide reaching the posterior retina within one hour[1]
- PACAP-deficient mice show accelerated retinal degeneration, confirming that endogenous PACAP is required for normal retinal health[2]
- TAT-bound PACAP and VIP peptides protected retinal neurons in ischemic models by penetrating cell membranes directly[4]
- A GHRH agonist enhanced retinal ganglion cell protection by macrophages, reducing ganglion cell loss in an optic neuropathy model[5]
- Exendin-4 (a GLP-1 receptor agonist) suppressed diabetic retinopathy markers in vivo and in vitro by reducing oxidative stress and inflammation[7]
- A meta-analysis of GLP-1 RA clinical trials found no increased risk of diabetic retinopathy with most agents, though semaglutide showed a possible transient signal[8]
PACAP: The Retina's Endogenous Protector
Pituitary adenylate cyclase activating polypeptide (PACAP) is expressed in retinal neurons and binds PAC1 receptors on photoreceptors, ganglion cells, and Muller glia. Its neuroprotective effects in the retina operate through multiple mechanisms: activation of anti-apoptotic Bcl-2 family proteins, reduction of oxidative stress through upregulation of antioxidant enzymes, and suppression of inflammatory cytokine release.
Szabadfi et al. (2012) demonstrated that PACAP knockout mice are more susceptible to retinal damage from monosodium glutamate excitotoxicity than wild-type mice, with more extensive photoreceptor loss and thinner retinal layers.[2] This finding established that endogenous PACAP provides tonic neuroprotection to the retina under normal conditions. The same group showed that PACAP protects against diabetic retinopathy in streptozotocin-induced diabetic rats, reducing retinal thinning and preserving electroretinogram (ERG) amplitudes.[3]
Van et al. (2021) extended this by showing that targeted deletion of PAC1 receptors specifically in retinal neurons enhanced neuron loss and axonopathy in a model of chronic neuroinflammation.[6] Without PAC1 receptor signaling, retinal neurons lost their resistance to inflammatory damage. This positions PAC1 receptor activation as a potential therapeutic target: drugs that enhance PACAP signaling at retinal PAC1 receptors could slow neurodegeneration.
Delivery Innovation: Cell-Penetrating PACAP
The challenge with PACAP is delivery. The peptide has a short plasma half-life and limited ability to cross the blood-retinal barrier. Atlasz et al. (2019) addressed this by conjugating PACAP and the related peptide VIP to TAT (transactivator of transcription), a cell-penetrating peptide derived from HIV-1 that ferries cargo across cell membranes.[4] TAT-bound PACAP and VIP protected retinal neurons in a bilateral carotid artery occlusion model of retinal ischemia. The TAT modification allowed the peptides to penetrate retinal cell membranes directly, bypassing the need for receptor-mediated entry and potentially increasing the concentration of neuroprotective peptide within at-risk cells.
Werling et al. (2014) explored whether shorter PACAP fragments could replicate the neuroprotective effects of the full-length peptide in chronic retinal hypoperfusion.[9] Various PACAP fragments and related peptides showed differential protective effects, with the 4-13 and 6-10 fragments demonstrating measurable retinal protection. Fragment-based approaches could simplify manufacturing and improve stability compared to full-length PACAP.
PEDF-Derived Peptides: Eye Drops That Reach the Retina
The most clinically advanced peptide approach for retinal degeneration may be PEDF-derived fragments. Pigment epithelium-derived factor (PEDF) is a 50-kDa glycoprotein secreted by retinal pigment epithelial cells that promotes photoreceptor survival. Full-length PEDF is too large for topical delivery, but small peptides derived from its active domains retain neuroprotective activity.
Bernardo-Colon et al. (2025) tested chemically synthesized PEDF-derived peptides (17-mer and H105A) as eye drops in two mouse models of retinitis pigmentosa.[1] The results were striking. Approximately 10% of applied peptide reached the posterior retina within one hour after topical application, with 1-5% remaining at 6-24 hours. Daily treatment with H105A eye drops preserved up to 75% of photoreceptors after one week in rd10 mice (a model of autosomal recessive RP). In human retinal organoids, H105A prevented photoreceptor death induced by oxidative stress.
This study matters for three reasons. First, it proves that a peptide can reach the retina through topical eye drops at therapeutically relevant concentrations, solving the delivery problem that limits many retinal peptide candidates. Second, the effect size (75% photoreceptor preservation) is large for a single-agent intervention. Third, human retinal organoid data provides translational evidence beyond rodent models. Eye drops are the most patient-friendly delivery route in ophthalmology, avoiding the intravitreal injections that current retinal therapies require.
GLP-1 Receptor Agonists: Unexpected Retinal Protection
GLP-1 receptor agonists, developed for diabetes and obesity, have emerged as potential retinal neuroprotectants through an unexpected pathway. GLP-1 receptors are expressed on retinal neurons and glial cells, and their activation reduces oxidative stress, neuroinflammation, and apoptosis in retinal tissue.
Liu et al. (2025) demonstrated that exendin-4, a GLP-1 receptor agonist, suppressed diabetic retinopathy in both streptozotocin-induced diabetic rats and high-glucose-exposed retinal cells.[7] Exendin-4 reduced retinal oxidative stress markers, decreased inflammatory cytokine expression, and inhibited apoptosis of retinal neurons. The mechanism involved activation of the PI3K/Akt survival pathway and suppression of NF-kB-mediated inflammation.
The clinical picture is more complex. Kapoor et al. (2023) conducted a meta-analysis of randomized clinical trials evaluating GLP-1 receptor agonists and diabetic retinopathy.[8] The analysis found that most GLP-1 RAs did not increase the risk of diabetic retinopathy. Semaglutide showed a possible transient increase in retinopathy events, which may be related to rapid blood glucose reduction (a known risk factor for early worsening of retinopathy) rather than a direct retinal effect. The distinction between GLP-1 agonists potentially helping versus harming the retina remains an active area of research. What makes GLP-1 agonists particularly interesting for retinal neuroprotection is that millions of patients already take them for diabetes and obesity. If their retinal protective effects are confirmed in dedicated ophthalmologic trials, repurposing an existing drug class would bypass decades of development time. The challenge is separating the indirect benefit of better glycemic control from any direct neuroprotective effect of GLP-1 receptor activation on retinal cells. Peptide therapies for diabetic eye disease represent one of the most active areas in ophthalmic peptide research.
GHRH Agonists: Retinal Protection Through Immune Modulation
Cen et al. (2021) discovered an unexpected retinal application for growth hormone-releasing hormone agonists.[5] In an optic neuropathy model, a GHRH agonist enhanced the neuroprotective activity of macrophages toward retinal ganglion cells. Optic neuropathies, including glaucoma, affect over 100 million people worldwide and involve progressive degeneration of retinal ganglion cells.
The mechanism is indirect: rather than acting on retinal neurons directly, the GHRH agonist modulated macrophage phenotype toward an anti-inflammatory, neurotrophic state. These "neuroprotective macrophages" then released factors that supported ganglion cell survival. This immune-mediated neuroprotection represents a different strategy than direct peptide-receptor activation on neurons. It also raises the possibility that growth hormone pathway peptides may have broader neuroprotective applications than their primary metabolic roles suggest.
The Delivery Challenge
Retinal peptide delivery remains the primary barrier to clinical translation. The retina sits behind the blood-retinal barrier, limiting what reaches it from systemic circulation. Current clinical retinal therapies (anti-VEGF antibodies) require intravitreal injection every 4-12 weeks, a procedure patients tolerate but do not prefer.
Peptides face additional challenges: short half-lives, susceptibility to enzymatic degradation, and limited tissue penetration. The field is addressing these through several strategies:
Topical eye drops. The Bernardo-Colon PEDF peptide data proves this route is viable for small peptides (17 amino acids). Not all peptides will penetrate the cornea and vitreous to reach the retina, but those that do offer the most practical delivery route.
Cell-penetrating peptide conjugation. TAT-PACAP demonstrates that attaching a membrane-penetrating sequence to a neuroprotective peptide increases intracellular delivery. Other cell-penetrating peptides (penetratin, polyarginine) are being explored for retinal applications.
Sustained-release intravitreal implants. Biodegradable polymer implants loaded with neuroprotective peptides could provide months of slow release from a single injection. CNTF has been tested in this format through Neurotech's NT-501 encapsulated cell technology, which releases CNTF continuously into the vitreous.
Fragment optimization. Werling's work on PACAP fragments shows that shorter peptides can retain biological activity while gaining stability and penetration advantages. Identifying the minimum pharmacophore for retinal neuroprotection could simplify delivery and manufacturing.
Where the Pipeline Stands
No neuroprotective peptide is approved for retinal degeneration. The closest candidates:
- CNTF (NT-501 implant): completed Phase 2 trials for geographic atrophy (dry AMD) and RP, showing photoreceptor preservation on OCT imaging but mixed functional outcomes
- PEDF-derived peptides (H105A): preclinical eye drop data in mice and human organoids; no human trials announced
- PACAP analogs: preclinical data across multiple retinal disease models; no clinical trials for retinal indications
- GLP-1 receptor agonists: already approved for systemic use; retinal effects being evaluated in ongoing diabetic retinopathy trials
- Rod-derived cone viability factor (RdCVF): a peptide-like thioredoxin that promotes cone survival; Phase 1/2 gene therapy trial (SPVN06) is underway
The distinction between these candidates matters. PACAP and PEDF target photoreceptor survival directly through receptor-mediated anti-apoptotic signaling. CNTF works indirectly through Muller glia. GHRH agonists modulate immune cell behavior. GLP-1 agonists reduce the metabolic stress that kills retinal neurons in diabetes. RdCVF supports cone photoreceptor metabolism by enhancing glucose uptake. Each addresses a different node in the degenerative cascade, which is why combination approaches, using two or more peptides targeting complementary pathways, may ultimately prove more effective than any single agent.
The gap between preclinical promise and clinical reality in retinal neuroprotection is wide. Many peptides that rescue photoreceptors in mouse models have failed to translate to human efficacy. The reasons include species differences in retinal anatomy, the challenge of maintaining therapeutic concentrations in the vitreous long enough to matter, and the difficulty of measuring neuroprotection in slow-progressing human diseases that take years to show functional decline.
What has changed is the delivery technology. Topical peptide eye drops, sustained-release implants, and gene therapy-based approaches for peptide expression all address the half-life and penetration problems that limited earlier generations of retinal neuroprotectants. The peptide biology was never the bottleneck. Getting the right peptide to the right retinal cells at the right concentration for long enough has been the challenge, and that problem is now yielding to engineering solutions.
The Bottom Line
Multiple neuroprotective peptide classes show retinal protection in preclinical models: PACAP (endogenous retinal protector, proven by knockout studies), PEDF-derived fragments (75% photoreceptor preservation via eye drops), GLP-1 agonists (reduced diabetic retinopathy markers), and GHRH agonists (immune-mediated ganglion cell protection). Delivery remains the primary translational barrier, but PEDF peptide eye drops, TAT-conjugated PACAP, and sustained-release CNTF implants represent advancing solutions. No neuroprotective peptide is yet approved for retinal degeneration, but the pipeline is deeper than ever.